Findings

What do systematic reviews say?

4,721 questions · 19,640 findings · 2,039 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,754 · 19.1%GRADE not reported 1,273 · 6.5%Very low 4,859 · 24.7%Low 5,568 · 28.4%Moderate 3,240 · 16.5%High 946 · 4.8%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

Improvement in quality of life · people with stroke or transient ischaemic attack

The review found no eligible studies for this question.

1 finding from 1 review

Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular events in… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Insulin sensitivity · people with stroke or transient ischaemic attack

1 finding from 1 review

Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular events in… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

Cardiac T2* value · or population: people with transfusion‐dependent beta thalassaemia

1 finding from 1 review

Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 191 participants
Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

MIC · or population: people with transfusion‐dependent beta thalassaemia

1 finding from 1 review

Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 138 participants
Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

LVEF (echocardiography) · or population: people with transfusion‐dependent beta thalassaemia

1 finding from 1 review

Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 136 participants
Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

Ferritin (µg/L) · or population: people with transfusion‐dependent beta thalassaemia

1 finding from 1 review

Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 187 participants
Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

Liver T2* value · or population: people with transfusion‐dependent beta thalassaemia

1 finding from 1 review

Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 127 participants
Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

LIC · or population: people with transfusion‐dependent beta thalassaemia

1 finding from 1 review

Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 123 participants
Moderate

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

Adverse events · or population: people with transfusion‐dependent beta thalassaemia

1 finding from 1 review

Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 234 participants
Very low

Ataluren vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with CF with at least one class I mutation (PTC)

1 finding from 1 review

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 506 participants
High

Ataluren vs placebo

Adverse events relating to treatment Scale: mild, moderate, severe and total · adults and children with CF with at least one class I mutation (PTC)

1 finding from 1 review

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 517 participants
Moderate

Ataluren vs placebo

Pulmonary exacerbations · adults and children with CF with at least one class I mutation (PTC)

1 finding from 1 review

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 232 participants
High

Ataluren vs placebo

Nutrition and growth Change in: a) weight (kg) b) BMI (kg/m2) c) height (m) · adults and children with CF with at least one class I mutation (PTC)

1 finding from 1 review

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 506 participants
High

Ataluren vs placebo

Sweat chloride level ‐ change from baseline Scale: mmol/L · adults and children with CF with at least one class I mutation (PTC)

1 finding from 1 review

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 194 participants
High

Ataluren vs placebo

Mortality rate · adults and children with CF with at least one class I mutation (PTC)

1 finding from 1 review

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 518 participants
High

Dextrose gel vs placebo

Hypoglycaemia · newborn infants at risk of neonatal hypoglycaemia

Dextrose gel leads to lower hypoglycaemia (investigator‐defined) compared with placebo (high certainty).

1 finding from 1 review

Oral dextrose gel to prevent hypoglycaemia in at‐risk neonates 2023 · Cochrane Headline outcomes only
RR 0.87 [0.79, 0.95]
2 studies · 2548 participants
High

Major neurological disability at 2 years of age (Defined as any of the following: legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy or developmental delay/intellectual impairment (developmental quoti... · newborn infants at risk of neonatal hypoglycaemia

Dextrose gel showed no clear difference in major neurological disability at 2 years of age (Defined as any of… compared with placebo (low certainty).

1 finding from 1 review

Oral dextrose gel to prevent hypoglycaemia in at‐risk neonates 2023 · Cochrane Headline outcomes only
RR 1 [0.59, 1.68]
2 studies · 1554 participants
Low

Dextrose gel vs placebo

Receipt of treatment for hypoglycaemia during initial hospital stay (investigator‐defined, any treatment ‐ oral dextrose gel, intravenous dextrose, or other drug therapy) during initial hospital stay (yes/no) · newborn infants at risk of neonatal hypoglycaemia

Dextrose gel showed no clear difference in receipt of treatment for hypoglycaemia during initial hospital stay… compared with placebo (moderate certainty).

1 finding from 1 review

Oral dextrose gel to prevent hypoglycaemia in at‐risk neonates 2023 · Cochrane Headline outcomes only
RR 0.89 [0.79, 1]
2 studies · 2548 participants
Moderate

Dextrose gel vs placebo

Receipt of intravenous treatment for hypoglycaemia (yes/no) · newborn infants at risk of neonatal hypoglycaemia

Dextrose gel showed no clear difference in receipt of intravenous treatment for hypoglycaemia (yes/no) compared with placebo (moderate certainty).

1 finding from 1 review

Oral dextrose gel to prevent hypoglycaemia in at‐risk neonates 2023 · Cochrane Headline outcomes only
RR 1.01 [0.68, 1.49]
2 studies · 2548 participants
Moderate

Dextrose gel vs placebo

Adverse events# (e.g. choking or vomiting at time of administration) · newborn infants at risk of neonatal hypoglycaemia

Dextrose gel showed no clear difference in adverse events# (e.g. choking or vomiting at time of administration) compared with placebo (moderate certainty).

1 finding from 1 review

Oral dextrose gel to prevent hypoglycaemia in at‐risk neonates 2023 · Cochrane Headline outcomes only
RR 1.22 [0.64, 2.33]
2 studies · 2510 participants
Moderate